What question did this study set out to answer?

Synthesize published literature and multi-institutional expert experience into clinical best-practice recommendations for identifying and managing mogamulizumab-associated rash.

November 23, 2021Dermatology and TherapyOpen Access

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management

View Full Paper

Ask AI

Bookmark

Authors

AMAmy MusiekWashington University in St. Louis KRKerri E. RiegerPalo Alto University MBM. BagotInserm

Discussion

Member takes

Implication

Expert consensus report outlines strategies for mogamulizumab-induced rash in cutaneous lymphoma, highlighting the role of biopsy and multidisciplinary care.

Key Points

Synthesize published literature and multi-institutional expert experience into clinical best-practice recommendations for identifying and managing mogamulizumab-associated rash.
Integrated published evidence from clinical trials and real-world studies with practical consensus guidelines from experienced oncologists, dermatologists, and pathologists treating mycosis fungoides and Sézary syndrome.
Mogamulizumab-induced rash is a prevalent adverse event whose protean clinical and histopathological presentation often mimics active mycosis fungoides or Sézary syndrome.
Accurate differentiation between drug-related rash and cancer progression requires diagnostic biopsy confirmation.
Effective clinical resolution is achieved through topical or systemic corticosteroid therapy guided by multidisciplinary coordination across oncology, dermatology, and pathology.

Cite This Study

Musiek et al. (2021) studied this question.

synapsesocial.com/papers/6aa8f23ad75aeabedda33566 https://doi.org/10.1007/s13555-021-00624-7

View Full Paper

Ask AI

Bookmark

Implication

Expert consensus report outlines strategies for mogamulizumab-induced rash in cutaneous lymphoma, highlighting the role of biopsy and multidisciplinary care.

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management

Discussion

Member takes

Implication

Key Points

Cite This Study

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider